Searching for moderators and mediators of pharmacological treatment effects in children and adolescents with anxiety disorders

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 42, Issue 1, 2003, Pages 13-21

  Vitiello, B ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Anxiety; Fluvoxamine; Mediators; Moderators; Pharmacology; Treatment

Indexed keywords

FLUVOXAMINE; PLACEBO; ANXIOLYTIC AGENT;

ANXIETY DISORDER; ARTICLE; ATTENTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EDUCATION; FAMILY; HUMAN; INCOME; MAJOR CLINICAL STUDY; MEDIATOR; PARENT; PATIENT COMPLIANCE; PEDIATRICS; PREDICTION; PRIORITY JOURNAL; RATING SCALE; REGRESSION ANALYSIS; SOCIAL PHOBIA; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; SYMPTOM; TIME; TREATMENT OUTCOME; ADOLESCENT; CHILD; EPIDEMIOLOGY; FEMALE; MALE; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; CHILD; EPIDEMIOLOGIC FACTORS; FEMALE; FLUVOXAMINE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 0037209095     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004583-200301000-00006     Document Type: Article

References (41)

1. Allgulander C (1999), Paroxetine in social anxiety disorder: a randomized, placebo-controlled study. Acta Psychiatr Scand 100:193-198
2. Aman MG, Marks RE, Turbott SH, Wilsher CP, Merry SN (1991), Clinical effects of methylphenidate and thioridazine in intellectually subaverage children. J Am Acad Child Adolesc Psychiatry 30:246-256
3. Baron RM, Kenny DA (1986), The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 51:1173-1182
4. Berman J, Weems CF, Silverman WK, Kurtines WM (2000), Predictors of outcome in exposure-based cognitive and behavioral treatments for phobic and anxiety disorders in children. Behav Ther 31:713-731
5. Brent DA, Kolko DJ, Birmaher B et al. (1998), Predictors of treatment efficacy in a clinical trial of three psychosocial treatments for adolescent depression. J Am Acad Child Adolesc Psychiatry 37:906-914
6. Cohen J (1988), Statistical Power Analysis for the Behavioral Sciences, 2nd ed. Hillsdale, NJ: Erlbaum
7. Davidson JRT (2001), Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 62(S11):46-50
8. Freedman LS, Simon R, Foulkes MA et al. (1995), Inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993: the perspective of NIH clinical trialists. Control Clin Trials 16:277-285
9. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E (2000), Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA 283:3082-3088
10. Guy W (1976), ECDEU Assessment Manual for Psychopharmacology, Revised (Publication ADM 91-338). Rockville, MD: US Department of Health and Human Services
11. Hughes CW, Emslie G, Kowatch R, Weinberg W, Rintelmann J, Rush AJ (2000), Clinician, parent, and child prediction of medication or placebo in double-blind depression study. Neuropsychopharmacology 2:591-594
12. Kaufman AS, Kaufman NL (1987), Kaufman Brief Intelligence Test (K-BIT). Odessa, FL: Psychological Assessment Resources
13. Kaufman J, Birmaher B, Brent D et al. (1997), Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980-988
14. Kazdin A (2001), Bridging the enormous gap of theory with therapy research and practice. J Clin Child Psychol 30:59-66
15. Kendall PC, Brady EU, Verduin TL (2001), Comorbidity in childhood anxiety disorders and treatment outcome. J Am Acad Child Adolesc Psychiatry 40:787-794
16. Kendall PC, Flannery-Schroeder E, Panichelli-Mindel SM, Southam-Gerow M, Henin A, Warman M (1997), Therapy for youths with anxiety disorders: a second randomized clinical trial. J Consult Clin Psychol 65:366-380
17. Klein RG, Koplewicz HS, Kanner A (1992), Imipramine treatment of children with separation anxiety disorder. J Am Acad Child Adolesc Psychiatry 31:21-28
18. Kowatch RA, Carmody TJ, Emslie GJ, Rintelmann JW, Hughes CW, Rush AJ (1999), Prediction of response to fluoxetine and placebo in children and adolescents with major depression: a hypothesis generating study. J Affect Disord 54:269-276
19. March JS, Biederman J, Wolkow R et al. (1998), Sertraline in children and adolescents with obsessive-compulsive disorder. JAMA 280:1752-1756
20. March JS, Curry JF (1998), Predicting the outcome of treatment. J Abnorm Child Psychol 26:39-51
21. Martenyi F, Dossenbach M, Mraz K, Metcalfe S (2001), Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. Eur Neuropsychopharmacol 11:227-232
22. Montgomery SA (1998), Implications of the severity of social phobia. J Affect Disord 50:S17-S22
23. MTA Cooperative Group (1999), Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder (ADHD). Arch Gen Psychiatry 56:1088-1096
24. National Institutes of Health (1994), NIH Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research. Fed Reg March 28, part VIII (59 FR 14508-14513)
25. Paykel ES, Hollyman JA, Freeling P, Sedwick P (1988), Predictors of therapeutics benefit from amitriptyline in mild depression: a general practice placebo-controlled trial. J Affect Disord 14:83-95
26. Pine DS, Cohen P, Gurley D, Brook JS, Ma Y (1998), The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders. Arch Gen Psychiatry 55:56-64
27. Poznanski EO, Freeman LN, Mokros HB (1985), Children's Depression Rating Scale-Revised. Psychopharmacol Bull 21:979-989
28. Research Units on Pediatric Psychopharmacology Anxiety Study Group (2001), Fluvoxamine treatment of anxiety disorders in children and adolescents. N Engl J Med 344:1279-1285
29. Research Units on Pediatric Psychopharmacology Anxiety Study Group (2002), The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties. J Am Acad Child Adolesc Psychiatry 41:1061-1069
30. Riddle MA, Reeve EA, Yaryura-Tobias JA et al. (2001), Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 40:222-229
31. Ryan ND, Varma D (1998), Child and adolescent mood disorders: experience with serotonin-based therapies. Biol Psychiatry 44:336-340
32. Rynn MA, Siqueland L, Rickels K (2001), Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry 158:2008-2014
33. Schatzberg AF, Kraemer HC (2000), Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression. Biol Psychiatry 47:736-744
34. Schneier FR, Goetz D, Campeas R, Fallon B, Marshall R, Liebowitz MR (1998), Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry 172:70-77
35. Schweizer E, Rynn M, Mandos LA, Demartinis N, Garcia-Espana F, Rickels K (2001), The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trial. Int Clin Psychopharmacol 16:137-143
36. Shaffer D, Fisher P, Dulcan MK et al. (1996), The NIMH Diagnostic Interview Schedule for Children Version 2.3 (DISC-2 3): description, acceptability, prevalence rates, and performance in the MECA study. J Am Acad Child Adolesc Psychiatry 35:865-877
37. Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B (1999), Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 156:756-760
38. Van Vliet IM, den Boer JA, Westenberg HGM (1994), Psychopharmacological treatment of social phobia: a double blind placebo controlled study with fluvoxamine. Psychopharmacology 115:128-134
39. Vitiello B, Jensen PS (1995), Developmental perspectives in pediatric psychopharmacology. Psychopharmacol Bull 31:75-81
40. Wilcox CS, Cohn JB, Linden RD, Heiser JF, Lucas PB, DeAnn LM (1992), Predictor of placebo response: a retrospective analysis. Psychopharmacol Bull 28:157-162
41. Wood AJ (1998), Ethnic differences in drug disposition and response. Ther Drug Monit 20:525-526